Intellipharmaceutics Cash Flow - Annual (NASDAQ:IPCI)

Add to My Stocks
$2.76 $0.01 (0.36%) IPCI stock closing price Sep 20, 2018 (Closing)

The Intellipharmaceutics cash flow statement is one of the important reports considered by investors doing a fundamental analysis of the company. In simple terms, the cash flow statement measures the cash that has come into the company, and the cash that has gone out during a given period, while the other statements, the income statement and balance sheet, give details about Intellipharmaceutics profits and Intellipharmaceutics debt. The cash flow statement is essetial while conducting the Intellipharmaceutics cash flow analysis and can be used to measure the operating performance of Intellipharmaceutics compared to various industry peers like DMPI stock and ULUR stock. Intellipharmaceutics had an outflow of $-6.1M from operating activities, $5.68M inflow due to financing activities, and $-1.82M outflow due to investing activities for 2017.

View details of Intellipharmaceutics cash flows for latest & last 10 financial years
show more
View Previous Years
View Next Years
Fiscal year is Dec - Nov2017201620152014201320122011201020092008
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow----------
Net Increase (Decrease) in Assets Liabilities-0.03M1.1M2.76M-0.13M-1.47M-0.53M1.18M-1.84M--0.49M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net2.26M2.39M-1.89M5.64M-1.43M-3.51M1.16M-1.14M
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-1.82M-0.51M-0.43M-0.76M-0.12M-1.03M-0.26M-0.13M--
Acquisition Disposition of Subsidiaires----------
Increase (Decrease) in Investments----------
Other Cash Inflow (Outflow) from Investment Activities----------
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares6.86M10.16M2.02M7.46M6.71M5.18M12.09M---
Issuance (Repayment) of Debt Securities-0.16M-0.02M-0.02M-0.05M1.45M-0.04M-0.02M-0.03M--
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities-1.02M-0.98M-0.25M-1.45M-0.83M-0.77M-0.8M-0.87M--
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash-----0.01M-----
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year4.14M1.75M4.23M--4.81M-8.01M-22.6M
Cash & Equivalents at Year End1.89M4.14M1.75M4.23M--4.81M--8.21M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Click here to view our AMNEAL PHARMACT financial analysis

While Intellipharmaceutics stock price history provides the price history of a stock, Intellipharmaceutics stock comparison chart shows the same in comparison to peers, and cash flow statements provide cash position of the company. Common terms used in the statement of cash flows are:

  • Intellipharmaceutics had a Net Change in Cash and Cash Equivalents of $-2.24M for the latest year 2017. If a firm is able to grow its cash, it is considered to be a positive signal and could lead to a jump in the Intellipharmaceutics stock price, albeit too much cash on hand can imply the company has no or limited avenues for growth in which to invest this cash.
  • The cash generated from the core business or operations was a negative at $-6.1M for Intellipharmaceutics in the latest 2017. For an internet company, this would include all those activities which are involved in eventually selling advertisement space on its website or any online service.
  • Cash from investing stood at a negative value of $-1.82M for IPCI stock. A company with surplus cash usually thinks of re-investing it in the form of buying fixed assests, or purchasing plant/ machinery which will help grow the business further. By looking at cash flow from investment activities one can check where the company is putting its cash.
  • Inflow of cash in the form of bank loans and shareholders equity, and outflow of cash because of dividend payments, share repurchase payments etc. come under financing activities. The cash generated from these activities was $5.68M for Intellipharmaceutics.

Key Financial Ratios For Intellipharmaceutics Cash Flow

Annual Cash Flow Statements For IntelliPharmaCeutics Intl Inc (USA) Peers

Alexza cash flow, AMNEAL PHARMACT cash flow, DelMar Pharma cash flow, KemPharma cash flow, Uluru cash flow